Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TBPH | US
-0.11
-1.34%
Healthcare
Biotechnology
30/06/2024
04/10/2024
8.10
8.14
8.21
8.07
Theravance Biopharma Inc. a biopharmaceutical company discovers develops and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI a once-daily nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program as well as Viatris Inc. Theravance Biopharma Inc. was incorporated in 2013 and is based in George Town the Cayman Islands.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Weakness based on declining price with high volume
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
20.8%1 month
18.4%3 months
50.2%6 months
45.9%-
9.31
2.05
0.24
0.13
-9.69
5.59
-0.05
-39.17M
396.27M
396.27M
-
-89.46
-
3.70
-19.27
23.82
21.38
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.40
Range1M
0.54
Range3M
2.98
Rel. volume
1.13
Price X volume
1.94M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Foghorn Therapeutics Inc | FHTX | Biotechnology | 7.83 | 433.22M | -6.00% | n/a | -285.69% |
Esperion Therapeutics Inc | ESPR | Biotechnology | 2.16 | 423.85M | 18.68% | n/a | -161.71% |
Verve Therapeutics Inc. Common Stock | VERV | Biotechnology | 5 | 423.12M | 4.17% | n/a | 13.27% |
Taysha Gene Therapies Inc | TSHA | Biotechnology | 2.01 | 417.91M | -1.95% | n/a | 53.02% |
LRMR | LRMR | Biotechnology | 6.65 | 408.81M | 5.72% | n/a | 2.65% |
Sage Therapeutics Inc | SAGE | Biotechnology | 6.64 | 405.37M | -4.87% | n/a | 0.22% |
Voyager Therapeutics Inc | VYGR | Biotechnology | 7.04 | 383.91M | 20.96% | 21.67 | 13.99% |
Biomea Fusion Inc. Common Stock | BMEA | Biotechnology | 10.48 | 379.48M | 3.46% | n/a | 9.95% |
ZVRA | ZVRA | Biotechnology | 7.2 | 378.85M | 1.12% | n/a | 183.10% |
C4 Therapeutics Inc | CCCC | Biotechnology | 5.38 | 373.04M | -0.92% | n/a | 27.69% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -9.69 | 0.76 | Cheaper |
Ent. to Revenue | 5.59 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 2.05 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 50.25 | 74.67 | Lower Risk |
Debt to Equity | 0.24 | -1.82 | Expensive |
Debt to Assets | 0.13 | 0.26 | Cheaper |
Market Cap | 396.27M | 3.73B | Emerging |